-
Je něco špatně v tomto záznamu ?
Fibroblast growth factor receptors across urothelial carcinoma landscape
IE. Ertl, SF. Shariat, H. Mostafaei, D. Ilijazi, Y. Loriot,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- chinoxaliny terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- karcinom z přechodných buněk farmakoterapie patologie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory močového měchýře farmakoterapie patologie MeSH
- protinádorové látky terapeutické užití MeSH
- pyrazoly terapeutické užití MeSH
- receptor fibroblastových růstových faktorů, typ 3 MeSH
- receptory fibroblastových růstových faktorů antagonisté a inhibitory terapeutické užití MeSH
- urologické nádory farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
PURPOSE OF REVIEW: Fibroblast growth factor receptor (FGFR) signalling, especially induced by FGFR3, is a crucial factor in the pathogenesis of urothelial carcinoma and was therefore extensively studied over the last decades. In this review, we summarize the most relevant findings of the past two years. RECENT FINDINGS: Recent studies support the concept that FGFR3 mediates a pathway of urothelial carcinogenesis associated with low malignant potential. FGFR3 may represent a highly accurate biomarker for diagnosis and prediction of recurrence, progression or therapy response. The pan FGFR-inhibitor erdafitinib was recently approved for urothelial carcinoma, whereas several other FGFR-targeted drugs are currently undergoing clinical trials. SUMMARY: Numerous recent studies focus on the role of FGFR3 in different urothelial carcinoma subtypes and its potential clinical application as noninvasive biomarker, as well as therapeutic target.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028041
- 003
- CZ-PrNML
- 005
- 20210114152845.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000782 $2 doi
- 035 __
- $a (PubMed)32452999
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ertl, Iris E $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 245 10
- $a Fibroblast growth factor receptors across urothelial carcinoma landscape / $c IE. Ertl, SF. Shariat, H. Mostafaei, D. Ilijazi, Y. Loriot,
- 520 9_
- $a PURPOSE OF REVIEW: Fibroblast growth factor receptor (FGFR) signalling, especially induced by FGFR3, is a crucial factor in the pathogenesis of urothelial carcinoma and was therefore extensively studied over the last decades. In this review, we summarize the most relevant findings of the past two years. RECENT FINDINGS: Recent studies support the concept that FGFR3 mediates a pathway of urothelial carcinogenesis associated with low malignant potential. FGFR3 may represent a highly accurate biomarker for diagnosis and prediction of recurrence, progression or therapy response. The pan FGFR-inhibitor erdafitinib was recently approved for urothelial carcinoma, whereas several other FGFR-targeted drugs are currently undergoing clinical trials. SUMMARY: Numerous recent studies focus on the role of FGFR3 in different urothelial carcinoma subtypes and its potential clinical application as noninvasive biomarker, as well as therapeutic target.
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a karcinom z přechodných buněk $x farmakoterapie $x patologie $7 D002295
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a pyrazoly $x terapeutické užití $7 D011720
- 650 _2
- $a chinoxaliny $x terapeutické užití $7 D011810
- 650 _2
- $a receptor fibroblastových růstových faktorů, typ 3 $7 D051498
- 650 _2
- $a receptory fibroblastových růstových faktorů $x antagonisté a inhibitory $x terapeutické užití $7 D017468
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
- 650 _2
- $a urologické nádory $x farmakoterapie $7 D014571
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Department of Urology, Weill Cornell Medical College, New York, USA. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Department of Urology, University of Jordan, Amman, Jordan.
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- 700 1_
- $a Ilijazi, Dafina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Loriot, Yohann $u Department of Cancer Medicine, Gustave Roussy Institute, INSERM 981, Cancer Campus, Grand Paris, University of Paris-Saclay, Villejuif, France.
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 4 (2020), s. 557-565
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32452999 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152843 $b ABA008
- 999 __
- $a ok $b bmc $g 1608376 $s 1119221
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 4 $d 557-565 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20210105
